A team at Rice University is designing wearable technology that can be used for navigation for users with visual and auditory impairments. Photo by Brandon Martin/Rice University

A group of Rice researchers have tapped into the sense of touch to improve how wearable technology can communicate with its user.

Barclay Jumet, a mechanical engineering PhD student at Rice working in the labs of Daniel Preston and Marcia O’Malley, published the findings in the August issue of “Device.” The study outlines the group's new system of haptic accessories that rely heavily on fluidic control over electrical inputs to signal or simulate touch to a wearer. The research was supported by the National Science Foundation, the Rice University Academy of Fellows, and the Gates Millennium Scholars Program.

The accessories include a belt and textile sleeves, which deliver haptic cues like vibration, tapping and squeezing through pressure generated by a lightweight carbon dioxide tank attached to the belt. The sleeve contains up to six quarter-sized pouches that inflate with varying force and frequency, depending on what is being communicated to the wearer.

Marcia O'Malley (from left), Barclay Jumet and Daniel Preston developed a wearable textile device that can deliver complex haptic cues in real time to users on the go. Photo by Brandon Martin/Rice University

The team says the wearables have uses for those with visual and auditory impairments and offer a slimmed-down design compared to other bulky complex haptic wearables. The wearables are also washable and repairable, which gives them more everyday uses.

To test the system's usability, the team guided a user on a mile-long route through Houston, signaling haptic cues for forward, backward, left or right through the devices.

“In the future, this technology could be directly integrated with navigational systems, so that the very textiles making up one’s clothing can tell users which way to go without taxing their already overloaded visual and auditory senses—for instance by needing to consult a map or listen to a virtual assistant,” Jumet said in a release from Rice.

O’Malley, chair of the Department of Mechanical Engineering, said the system could also work in tandem with Cochlear implants and make lip-reading easier for users in noisy environments by directing users to sources of sound.

Jumet also sees uses outside of the medical space.

“Instead of a smart watch with simple vibrational cues, we can now envision a ‘smart shirt’ that gives the sensation of a stroking hand or a soft tap on the torso or arm,” he said in the release. “Movies, games and other forms of entertainment could now incorporate the sense of touch, and virtual reality can be more comfortable for longer periods of time.”


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”